Exact Sciences set to rally on positive top-line results from pivotal BLUE-C studyProactive Investors • 06/21/23
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary CollaborationsPRNewsWire • 06/21/23
Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive ScreeningPRNewsWire • 06/20/23
Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?Zacks Investment Research • 06/08/23
Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023PRNewsWire • 05/26/23
These stock pickers led the health-fund category over the past 5 years. Here's where they're investing now.Market Watch • 05/22/23
EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGSPRNewsWire • 05/17/23
Exact Sciences positioned for a solid year after ‘impressive' 1Q, broker saysProactive Investors • 05/16/23
A Bull Market Is Coming: 1 Supercharged Growth Stock to Buy Hand Over Fist Before It Soars 164%, According to Wall StreetThe Motley Fool • 05/14/23